Research Article

Comparison of The Expression Levels of PI3K/Akt Pathway Factors in Parkinson’s Disease and Lung Cancer

Volume: 8 Number: 2 November 12, 2018
  • Elif Şanlı *
  • Nazlı Yalçınkaya
  • Erdem Tüzün
TR EN

Comparison of The Expression Levels of PI3K/Akt Pathway Factors in Parkinson’s Disease and Lung Cancer

Abstract

DOI: 10.26650/experimed.2018.18003


Objectives: Parkinson’s disease (PD) is a common neurodegenerative disorder that affects >0.2% of the population aged >40 years. Several studies have reported a low prevalence of cancer in individuals with PD. Therefore, the PI3K/Akt signaling pathway has received increasing research attention. Investigating variations in expression levels of components associated with this pathway might aid in improving novel treatment methods and biomarkers for PD.

Material and Method: We evaluated expression levels of components of the DJ-1-PI3K/Akt signaling pathway in the peripheral blood mononuclear cells of patients with PD, those with lung cancer (LC), and healthy controls and attempted to identify a possible correlation between expression levels and clinical features of PD.

Results: Levels of phosphatase and tensin homolog (PTEN) and apoptosis-inducing factor-1 significantly decreased, whereas those of insulin-like growth factor 1 (IGF-1) significantly increased in patients with PD than in healthy controls. In patients with LC, levels of PTEN, caspase-3, and α-synuclein significantly increased, whereas those of IGF-1 significantly decreased. Furthermore, a correlation was observed between the clinical subtypes of PD and levels of α-synuclein, IGF-1, caspase-3, DJ-1, mechanistic target of rapamycin, Mdm2, and Akt-1 factors.

Conclusion: Patients with PD showed decreased expression levels of proapoptotic PTEN and increased levels of components of the antiapoptotic PI3K/Akt pathway, which suggests an activation of the antiapoptotic pathway to compensate for the increased neuronal destruction in PD. The correlation between expression levels of components of several PI3K/Akt signaling pathway and clinical parameters suggests that these factors can be used as disability and prognostic markers in patients with PD. Decreased expression levels of antiapoptotic factors in patients with PD having postural instability, in particular, suggests a close relationship between neuronal destruction and this symptom.

Keywords

References

  1. 1. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 62: 10-5.
  2. 2. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s Disease: Variation by Age, Gender, and Race/Ethnicity. Am J Epidemiol 2003; 157: 1015-22.
  3. 3. Hirsch E, Graybiel A, Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 1988; 334(6180): 345-8.
  4. 4. Dias V, Junn E, Mouradian MM. The role of oxidative stress in parkinson’s disease. J Parkinsons Dis 2013; 3: 461-91.
  5. 5. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson’s disease. Ann Neurol 1985; 17: 505-9.
  6. 6. Olsen J, Friis S, Frederiksen K. Malignant Melanoma and Other Types of Cancer Preceding Parkinson Disease. Epidemiology 2006; 17: 582-7.
  7. 7. D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G, et al. Tumor diagnosis preceding Parkinson’s disease: A case-control study. Mov Disord 2004; 19: 807-11.
  8. 8. Elbaz A, Peterson B, Yang P, Van Gerpen J, Bower J, Maraganore D, et al. Nonfatal cancer preceding parkinson’s disease: a case-control study. Epidemiology 2002; 13: 157-64.

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Research Article

Authors

Elif Şanlı * This is me

Nazlı Yalçınkaya This is me

Erdem Tüzün This is me

Publication Date

November 12, 2018

Submission Date

September 13, 2018

Acceptance Date

September 14, 2018

Published in Issue

Year 2018 Volume: 8 Number: 2

APA
Şanlı, E., Yalçınkaya, N., & Tüzün, E. (2018). Comparison of The Expression Levels of PI3K/Akt Pathway Factors in Parkinson’s Disease and Lung Cancer. Experimed, 8(2), 52-57. https://izlik.org/JA87WA25JB
AMA
1.Şanlı E, Yalçınkaya N, Tüzün E. Comparison of The Expression Levels of PI3K/Akt Pathway Factors in Parkinson’s Disease and Lung Cancer. Experimed. 2018;8(2):52-57. https://izlik.org/JA87WA25JB
Chicago
Şanlı, Elif, Nazlı Yalçınkaya, and Erdem Tüzün. 2018. “Comparison of The Expression Levels of PI3K Akt Pathway Factors in Parkinson’s Disease and Lung Cancer”. Experimed 8 (2): 52-57. https://izlik.org/JA87WA25JB.
EndNote
Şanlı E, Yalçınkaya N, Tüzün E (November 1, 2018) Comparison of The Expression Levels of PI3K/Akt Pathway Factors in Parkinson’s Disease and Lung Cancer. Experimed 8 2 52–57.
IEEE
[1]E. Şanlı, N. Yalçınkaya, and E. Tüzün, “Comparison of The Expression Levels of PI3K/Akt Pathway Factors in Parkinson’s Disease and Lung Cancer”, Experimed, vol. 8, no. 2, pp. 52–57, Nov. 2018, [Online]. Available: https://izlik.org/JA87WA25JB
ISNAD
Şanlı, Elif - Yalçınkaya, Nazlı - Tüzün, Erdem. “Comparison of The Expression Levels of PI3K Akt Pathway Factors in Parkinson’s Disease and Lung Cancer”. Experimed 8/2 (November 1, 2018): 52-57. https://izlik.org/JA87WA25JB.
JAMA
1.Şanlı E, Yalçınkaya N, Tüzün E. Comparison of The Expression Levels of PI3K/Akt Pathway Factors in Parkinson’s Disease and Lung Cancer. Experimed. 2018;8:52–57.
MLA
Şanlı, Elif, et al. “Comparison of The Expression Levels of PI3K Akt Pathway Factors in Parkinson’s Disease and Lung Cancer”. Experimed, vol. 8, no. 2, Nov. 2018, pp. 52-57, https://izlik.org/JA87WA25JB.
Vancouver
1.Elif Şanlı, Nazlı Yalçınkaya, Erdem Tüzün. Comparison of The Expression Levels of PI3K/Akt Pathway Factors in Parkinson’s Disease and Lung Cancer. Experimed [Internet]. 2018 Nov. 1;8(2):52-7. Available from: https://izlik.org/JA87WA25JB